Structural and functional characterization of TgGSK3, a druggable kinase in Toxoplasma gondii

Diaz-Martin, Silvia; Swale, Christopher; Bellini, Valeria; Dobrescu, Irina; Wenker, Janine; Brenier-Pinchart, Marie-Pierre; Braun, Laurence; Tollec, Alwéna; Corrao, Charlotte; Couté, Yohann; Mas, Caroline; Laurent, Fabrice; Bowler, Matthew; Hakimi, Mohamed-Ali; Bougdour, Alexandre

doi:10.1038/s41467-025-64701-7

Download PDF

Article
Open access
Published: 05 November 2025

Structural and functional characterization of TgGSK3, a druggable kinase in Toxoplasma gondii

Nature Communications volume 16, Article number: 9765 (2025) Cite this article

5108 Accesses
5 Altmetric
Metrics details

Subjects

Abstract

Toxoplasma gondii and Cryptosporidium species are apicomplexan parasites of significant medical and veterinary importance. Although current therapeutic options for toxoplasmosis and cryptosporidiosis demonstrate notable efficacy, their clinical efficacy is often limited by suboptimal efficacy and frequent adverse effects. Moreover, therapeutic alternatives remain limited or nonexistent, particularly for cryptosporidiosis, for which nitazoxanide is currently the only approved medication to treat diarrhea in adults and children older than 1 year of age. To identify alternative therapeutic options for addressing these health challenges, we performed a phenotypic screening of an FDA-approved drug repurposing library against Toxoplasma. This screening identifies LY2090314 as a potent inhibitor of T. gondii and Cryptosporidium growth in mammalian cells. Through a target deconvolution strategy combining forward genetics, transcriptome sequencing, and computational mutation analysis, we elucidate the parasiticidal mechanism of LY2090314 and demonstrate that TgGSK3 kinase is its primary molecular target. We also report the first X-ray crystal structure of LY2090314 bound to TgGSK3, resolved at 2.1 Å, which reveals an interaction mode characteristic of type I ATP-competitive inhibitors. Furthermore, interactome analysis uncovers functional connections between TgGSK3 and key cytoskeletal and signaling regulators, providing insights into compound’s effects. Collectively, these findings validate TgGSK3 as a promising therapeutic target for toxoplasmosis and offer mechanistic insights into apicomplexan GSK3 biology.

Introduction

Infectious diseases caused by intracellular single-celled parasites of the Apicomplexa phylum, such as Plasmodium, Toxoplasma, and Cryptosporidium, pose significant public health challenges worldwide¹. These parasites, responsible for malaria, toxoplasmosis, and cryptosporidiosis, respectively, affect millions of individuals worldwide, causing significant morbidity and mortality, particularly in low-income countries, emphasizing the urgent need for effective treatments.

Malaria affects over 240 million people worldwide, with an estimated 608,000 deaths reported in 2022 (World Health Organization, World Malaria Report 2023²). Toxoplasmosis is a widespread zoonotic infection, with nearly a third of the world’s population being seropositive³. While acute primary infection is often self-limiting and typically resolves without specific treatment in healthy adults, a subclinical infection persists for life in infected individuals, constituting the chronic phase of toxoplasmosis. In the absence of sustained immunity, reactivation of latent forms of T. gondii can lead to severe, potentially life-threatening disease, particularly in immunocompromised individuals such as AIDS patients, transplant recipients, and those undergoing chemotherapy⁴. Severe cases may also arise during congenital transmission of the parasite to an unborn child. Additionally, life-threatening acute primary infections have been reported in healthy adults, particularly in regions of South America and Africa^5,6,7,8,9,10. These cases are potentially linked to mouse-virulent atypical strains circulating in these regions, which may exhibit greater virulence in humans compared to the canonical strains from Middle East, Europe, and North America¹¹. Such strain-specific differences likely contribute to the variability in clinical severity in humans observed across different regions^11,12,13.

While current medications are effective against Apicomplexa-mediated diseases, the persistent threat of drug resistance and adverse side effects, coupled with limited alternatives, underscores the critical need for the development of new, safe, and economical classes of small-molecule drugs. The current standard treatment for toxoplasmosis, a combination of pyrimethamine-sulfadiazine, is often associated with severe side effects, particularly in immunocompromised individuals¹⁴. Similarly, artemisinin-based combination therapies remain the cornerstone for malaria treatment; but the emergence and spread of resistance threaten their efficacy. Treatment options for cryptosporidial infections are even more restricted, relying primarily on nitazoxanide. The growing prevalence of drug-resistant parasites underscores the need to exploit the vulnerabilities of human parasites for therapeutic interventions by identifying novel druggable enzyme families.

In this study, we report the identification of the compound LY2090314 from a phenotypic screening of an FDA-approved drug repurposing library as an inhibitor of T. gondii growth in human cells. LY2090314, a maleimide-based kinase inhibitor originally developed to target human glycogen synthase kinase-3 (GSK3), has advanced through phase 1/2 clinical trials for treating advanced solid tumors¹⁵ and acute leukemia^16,17. Here, we present evidence that LY2090314 effectively inhibits T. gondii tachyzoite growth in vitro at sub-micromolar concentrations. Using a forward genetic approach based on transcriptome sequencing, we identified the T. gondii GSK3 (TgGSK3), a serine/threonine kinase, as the primary enzymatic target of LY2090314. Using an integrated structural biology approach, we uncover the inhibitory mechanism of LY2090314 on the enzymatic activity of the fitness-conferring TgGSK3 and provide a rationale for the resistance mechanisms conferred by the amino acid substitutions identified in the resistant parasite lines. Notably, we present the first X-ray crystal structure of LY2090314 bound to TgGSK3, revealing its mode of interaction characteristic of type I, ATP-competitive inhibitors. Genetic and biochemical evidence further indicate that TgGSK3 functions as a dimer. Overall, this study uncovers a novel and promising drug-target pair that could serve as the foundation for leveraging drug development against apicomplexan parasites.

Results

Phenotypic screening identifies LY2090314 as a potent inhibitor of T. gondii growth in vitro

In an effort to identify novel drug candidates against T. gondii parasites, the compound LY2090314 (compound #209) was identified, alongside altiratinib (compound #246¹⁸,), in a phenotypic screening of 514 approved molecules (Fig. 1a-b). This compound library, originally obtained from TargetMol, comprises FDA-approved drugs and advanced clinical candidates with known safety profiles and mechanistic diversity. It includes inhibitors targeting a wide array of druggable pathways such as kinases, ion channels, and metabolic enzymes, which may partly explain the relatively high hit rate observed in the primary screen. All hits identified in this screen were systematically followed up, with prioritization based on key criteria: (i) selective inhibition of parasite growth with minimal toxicity to host cells, (ii) activity against multiple apicomplexan species such as Cryptosporidium parvum, and (iii) feasibility of target deconvolution. In this context, LY2090314 was prioritized due to its potent and selective activity against T. gondii, nanomolar EC₅₀ values, favorable selectivity indices, and the successful identification of resistance-conferring mutations that enabled in-depth functional and structural characterization of its molecular target (see below).

**Fig. 1: Effectiveness of LY2090314 against apicomplexan parasites and human host cells.**

LY2090314 demonstrated selective inhibition of tachyzoite growth without affecting the human primary fibroblasts (HFFs) monolayer, as determined by Hoechst staining (Fig. 1a). Its effectiveness was validated at sub-micromolar concentrations, with measured half maximum effective concentration (EC₅₀) of 382 nM, which is comparable to pyrimethamine, the standard of care for toxoplasmosis (Fig. 1c and Supplementary Fig. 1a). Immunofluorescence assays using anti-GAP45 antibodies revealed a reduced intracellular parasite growth in LY2090314-treated parasites, accompanied by abnormal cell division (Fig. 1d). Remarkably, complete and sustained inhibition of growth was achieved at 600 nM LY2090314, as parasites were unable to grow and form plaques over the course of seven days (Fig. 1e). LY2090314 also showed low cytotoxicity on host cells (Fig. 1c and Supplementary Fig. 1b-c), particularly with the CellTox Green assay that measures changes in membrane integrity, resulting in a selectivity index of 892 and 808 for HFFs and the non-transformed ARPE-19 human retinal pigment epithelial cell line, respectively (Fig. 1f).

To evaluate whether LY2090314 also affects the chronic stage of the parasite, we assessed its activity against in vitro–induced bradyzoites using the ME49 pGRA1-dsRed2.0 pBAG1-mNeonGreen dual-reporter strain. Under bradyzoite-inducing conditions, treatment with 600 nM LY2090314 for 72 h resulted in a marked reduction in expression of the bradyzoite-specific markers BAG1, BCLA, and BSM^19,20, as measured by fluorescence intensity and immunostaining (Supplementary Fig. 1f–k). In contrast, expression of the tachyzoite-associated GRA1 reporter (dsRed2.0) was increased, indicating a shift in gene expression dynamics. These observations suggest that LY2090314 exerts a biological effect on in vitro bradyzoites, in agreement with the documented expression of TgGSK3 in this life stage (ToxoDB.org). In comparison, pyrimethamine treatment produced only modest changes in bradyzoite marker expression or GRA1 levels, indicating that LY2090314 may act through a distinct and potentially more specific mechanism to modulate developmental gene expression in T. gondii.

In addition to its efficacy against T. gondii, LY2090314 demonstrated potent efficacy in inhibiting the growth of Cryptosporidium parasites, with EC₅₀ values even lower than those observed for T. gondii, reflecting a higher antiparasitic potency (Fig. 1g and Supplementary Fig. 1d-e). Notably, these EC₅₀ values were also lower than those obtained for indirubin E804, another potential GSK3 inhibitor tested in parallel, further highlighting the superior efficacy of LY2090314. Indirubin E804 had been previously identified in a crystal structure of CpGSK3 (cgd4_240) in complex with the inhibitor (PDB ID: 3EB0). Note that no toxicity was detected up to 100 µM on HCT-8 human host cells (Fig. 1f), suggesting SI of a least 350 and 625 for C. parvum INRAE and IOWA strains, respectively (Fig. 1h).

To assess whether this inhibitory profile was specific to LY2090314, we examined several additional GSK3 inhibitors present in the original compound library. These included chemically diverse scaffolds such as aminopyrimidines, imidazopyridines, and thiadiazolidinones. None of these compounds significantly impaired T. gondii growth in vitro, suggesting limited efficacy or insufficient engagement with the parasite kinase (Fig. 1a). To further investigate the potential for GSK3 inhibition, we evaluated three additional GSK3 inhibitors with reported favorable safety profiles - BRD3731, SAR502250, and Tideglusib²¹. None of these compounds inhibited the proliferation of T. gondii or Cryptosporidium under the same experimental conditions (Fig. 1i-k), further underscoring the unique antiparasitic activity and specificity of LY2090314 against apicomplexan parasites.

Forward genetic screening identifies TgGSK3 as the enzyme targeted by LY2090314

To gain insights into the mechanism of action of LY2090314 in T. gondii, we used a previously developed workflow based on a forward genetic screen combined to RNA-Seq analysis, variant calling, and computational mutation discovery²². Central to this approach is that the gene mutated in more than one independently mutagenized resistant clone might be relevant to the mechanism of drug resistance, thereby alleviating the notoriously difficult molecular mapping of point mutations induced by mutagenic agents. First, eight independent ethyl methane sulphonate (EMS) mutagenesis experiments were performed, and the resulting mutagenized parasites were selected in the presence of 600 nM LY2090314 (Fig. 2a), which corresponds to ~1.6 times the EC₅₀ value. Resistant parasites emerged ~10 days later and were cloned by limited dilution (Supplementary Fig. 2a). A single clone from each mutagenesis experiment, designated A to H, was analyzed by whole-genome RNA-seq (Fig. 2a-d). To map the EMS-induced mutations conferring resistance against LY2090314, Illumina sequencing reads were aligned to the T. gondii GT1 reference genome. The assembled sequences were analyzed to identify single nucleotide variations (SNVs), small insertions, or short deletions using the parental strain as a reference, (see Methods section and Supplementary Data 2). By focusing on mutations in coding sequences, we identified a single gene, TGGT1_265330, which harbored SNVs leading to amino acid substitutions in each of the eight drug-resistant lines, absent in the parental strain. These mutations resulted in amino acid substitutions at the protein residues G54, H129, and T133 (Fig. 2e and Table 1). TGGT1_265330 encodes for a putative cell-cycle-associated protein kinase of 394 amino acids (Fig. 2e). Notably, each resistant clone harbored only a single point mutation in the TgGSK3 coding sequence, all identified mutations are confined to the serine/threonine protein kinase catalytic domain: G54D, affecting the first residue of the glycine triad, and H129D and T133M, both positioned in the hinge region preceding the C-lobe (Fig. 2e). The T133M mutation stands out as the most frequently observed, detected in six out of the eight sequenced clones. Bulk nanopore DNA sequencing analysis of the TGGT1_265330 alleles in the selected resistant parasite population exclusively identified the T133M mutation (Supplementary Fig. 3b). This observation suggests that the T133M mutation is either more prone to being induced by the EMS alkylating agent or provides a significant selective advantage compared to other mutations.

Fig. 2: Target identification for LY2090314 in T. gondii parasites. — **Fig. 2: Target identification for LY2090314 in *T. gondii* parasites.**

Table 1 Mutations found in candidate gene identified by whole-transcriptome analysis by RNA-Sequencing

Full size table

Phylogenetic analysis identified TGGT1_265330 as a member of the GSK3 clade, with conservation observed in other apicomplexan parasites, including Plasmodium falciparum and Cryptosporidium parvum (Fig. 2f and Supplementary Fig. 2b). This finding aligns with the observed inhibitory effect of LY2090314 on C. parvum growth in vitro (Fig. 1g and Supplementary Fig. 1d–e). Consequently, TGGT1_265330 is hereafter referred to as TgGSK3. Immunofluorescence analysis of intracellularly growing parasites revealed a nucleo-cytoplasmic localization of TgGSK3-HA (Fig. 3g; Supplementary Fig. 3c, d). TgGSK3 was identified as a fitness-conferring gene for tachyzoites, as its genetic disruption results in a fitness score of −4.12²³. Conditional knock-out of this kinase using the DiCre/loxP system²⁴ confirmed its essential role in tachyzoite growth (Fig. 3i and j), with complete protein depletion observed 48 h after Rapamycin treatment (Fig. 3g and h; Supplementary Fig. 3e and f).

**Fig. 3: Validation of TgGSK3 as the Target of LY2090314.**

To verify that the mutations in TGGT1_265330 were sufficient to confer resistance to LY2090314, we reintroduced each mutation identified in LY2090314-resistant parasites into the susceptible parental wild-type strain. This was achieved using the CRISPR/Cas9 system in combination with homology-directed repair for gene editing in T. gondii (Fig. 3a). After selection with LY2090314, emerging resistant parasites were cloned (Fig. 3b and c), and DNA sequencing confirmed that the mutations were correctly inserted into TGGT1_265330 (Supplementary Fig. 3a). In genome-edited parasites, the TGGT1_265330 point mutations G54D, H129D, and T133M conferred reduced susceptibility to LY2090314 compared to wild-type parasites, with EC₅₀ values increasing by ~2.9-fold, 4.5-fold, and 4.8-fold, respectively (Fig. 3b-e). CRISPR/Cas9–edited parasites carrying the G54D mutation exhibited lower resistance to LY2090314 compared to those harboring the H129D or T133M mutations. This observation aligns with results from EMS-mutagenized parasites and further suggests that the T133M or H129D mutations confer a higher level of resistance to the compound compared to the G54D mutation (Figs. 2b-c and 3b-e). Collectively, these data support the hypothesis that LY2090314 interferes with TgGSK3 activity, resulting in impaired parasite growth.

Structural insights into the mechanism of action of LY2090314 on TgGSK3 and resistance-conferring mutations

To investigate the molecular mechanism underlying LY2090314 inhibition, we produced the kinase domain of TgGSK3, excluding the intrinsically disordered N-terminal region, which was anticipated to hinder crystallization (Supplementary Fig. 4a). Using baculovirus-infected insect cells, two N-terminal truncations (starting at the residues 20 or 46) were successfully expressed and further purified. Successful co-crystallization conditions were achieved by incubating purified TgGSK3 with LY2090314 prior to final size exclusion chromatography and concentration. From these two constructs, two crystal types were obtained (statistics are shown on Supplementary Table 1): an orthorhombic system diffracting to 2.1 Å with one copy of TgGSK3 per asymmetric unit, and a monoclinic system diffracting at 3.0 Å with a crystallographic tetramer of TgGSK3 per asymmetric unit. Although LY2090314 density was clearly visible in both derived structures and in all copies of TgGSK3 within the monoclinic system, structural representations are derived from the orthorhombic crystal structure. TgGSK3 adopts the characteristic kinase fold, divided into two sub-domains classified as the N- and C-Lobe (Fig. 4a). Overall, TgGSK3 has high sequence (54% identity) and structural conservation (r.m.s.d. of 1.67 Å) to the human ortholog (Supplementary Fig. 4b), with most of the structural variation located within loops in the N-lobe (N-terminal region, Supplementary Fig. 2b). The LY2090314 compound is positioned within the ATP binding pocket, stabilizing phenylalanine 196, a key residue within the DFG motif, in an allosteric pocket bound or “DFG-in” conformation.

**Fig. 4: Structural basis of LY2090314 binding and inhibition of TgGSK3.**

LY2090314 is therefore classified as a “type I” inhibitor, competing with ATP for binding in the ATP binding site. The high-resolution electron density allowed for accurate modeling of the intricate folding of LY2090314 within the binding cavity (Supplementary Fig. 4c). Similar to other maleimide-based kinase inhibitors (Supplementary Fig. 4e and f), the maleimide group interacts with the hinge region of TgGSK3 (Fig. 4b), forming hydrogen bonds with the backbone residues E128 and I130 (Fig. 4b; Supplementary Fig 4d). In the vicinity of these direct ligand to protein bonds, LY2090314 also interacts indirectly with TgGSK3 by coordinating 3 water molecules within the cavity (Fig. 4b and c; Supplementary Fig. 4d). One of these water molecules forms a tetragonal coordination with both LY2090314 and 3 side chains of TgGSK3, including the catalytic lysine K76 (Fig. 4b and c; Supplementary Fig. 4d). It is worth noting that homology-based docking of LY2090314 would have resulted in a partially incorrect binding mode hypothesis. Indeed, the closest homologous compound, M97 (which binds to C-met and features a quinolinium side moiety instead of the imidazopyridine), is flipped in this perspective by 180° on the central maleimide moiety in this model (Supplementary Fig. 4e and f) while maintaining the same central maleimide hydrogen bonds. At the opposite side of LY2090314, the only direct hydrogen bond with an amino acid side chain involves the previously identified threonine 133 (Fig. 4b; Supplementary Fig. 4d), underscoring the importance of this residue in LY2090314 binding. To further investigate how these interactions are affected by the resistance conferring mutations, we used the recombinantly expressed TgGSK3 to assess the consequences of the three identified mutations (G54D, H129D and T133M) on compound binding and kinase activity rescue, comparing these results to the recombinant wild-type TgGSK3 (Fig. 4d and e).

To determine binding affinity, we used microscale thermophoresis to measure the apparent K_d (K_D) of LY2090314 against TgGSK3, which was found to be in the low nanomolar range at 34 nM (Fig. 4d). Similarly, the apparent IC₅₀ of TgGSK3 was estimated at 112 nM when measured using the kinase-Glo© endpoint ATP consumption assay in the presence of a HsGSK3 substrate peptide (Fig. 4e). The G54D only confers a small K_D and IC₅₀ increase (1.8 and 1.7-fold, respectively, Fig. 4e), which can be structurally explained by the location of this residue on the glycine-rich loop of TgGSK3 (Fig. 4b, Supplementary Fig. 5a). This loop folds to accommodate the fluorine moiety of LY209314, forming hydrophobic contacts with it through the C-α of the G54 residue. The mutation to an aspartate side chain does not directly affect the binding (Supplementary Fig. 5a), but rather induces changes in the ϕ and ψ dihedral angles, likely causing the slight reduction in apparent affinity. Similarly, the H129D mutation results in modest IC₅₀ increases (2.2-fold, Fig. 4e) but causes a more pronounced decrease in affinity towards TgGSK3 (6.7-fold, Fig. 4d). Again, the structural mechanism of resistance relies on a similar basis as the histidine side chain is oriented outside and does not directly interact with LY209314 (Supplementary Fig. 5b). Similarly to G54D, H129D also operates more indirectly by perturbing the upstream and downstream C-α dihedrals which are forming direct H-bonds with the inhibitor. Finally, the T133M mutation confers the most dramatic increase in K_D (18-fold, Fig. 4d) and IC₅₀ (5.3-fold, Fig. 4e). This is clearly explained structurally as the T to M side chain mutation will abolish one of the key H-bond interactions and at the same time introduce a significant steric clash to LY209314 binding (Supplementary Fig. 5c).

Homodimerization and redox regulation of TgGSK3: insights into its activation mechanism

Deciphering a protein’s biological function often hinges on uncovering its interacting partners. To probe the role and regulation of TgGSK3, we performed in vivo biotinylation using the proximity labeling approach employing BioID2, with TgGSK3 as the bait protein (Fig. 5a and b). The endogenously tagged TgGSK3-BioID2-HA fusion protein showed a nucleo-cytoplasmic distribution, consistent with the localization observed for the HA-tagged protein alone (Fig. 3g). The biotinylation activity of the TgGSK3-BioID2-HA fusion protein was validated using fluorophore-conjugated streptavidin. In the absence of exogenous biotin supplementation, the primary biotinylation signal was restricted to the apicoplast, reflecting the activity of metabolic enzymes that utilize biotin as a co-factor, as previously reported²⁵. However, with biotin supplementation, streptavidin signals were detected in the nucleus and cytoplasm, alongside a pronounced signal at the posterior pole of intracellular tachyzoites. These observations confirmed the biotinylation activity of the TgGSK3-BioID2-HA fusion protein and indicated that specific proteins in these subcellular compartments were labeled (Fig. 5a). To identify potential interacting partners or substrates of TgGSK3, biotinylated proteins were enriched from lysates using streptavidin affinity purification. As a control, a mock experiment was performed using parasites lacking the BioID2 fusion protein (RH ku80). Mass spectrometry-based proteomic analysis identified ~200 proteins with ≥5-fold enrichment in abundances in the two biological replicates obtained from TgGSK3-BioID2-HA expressing parasites compared to the mock control (Fig. 5b; Supplementary Data 3). Gene Ontology (GO) enrichment analysis revealed that these candidate interactors were associated with diverse molecular functions, including RNA binding (Fig. 5d). Notably, TgGSK3 was highly enriched ( > 60-fold) in the proximity labeling dataset, likely due to intramolecular biotinylation.

**Fig. 5: Identification of TgGSK3-interacting proteins.**

To further explore the TgGSK3 interactome, a yeast two-hybrid (Y2H) screen was performed using a T. gondii cDNA library as prey. The bait construct consisted of the catalytically inactive N-terminal TgGSK3^K76H mutant (amino acids 1–394) fused to the LexA DNA-binding domain (TgGSK3^K76H-LexA, Fig. 5c). This kinase-dead TgGSK3 mutant was intended to increase the likelihood of capturing substrate interactions²⁶. From a total of 47.4 million cDNA clones screened, 246 positive hits corresponding to 44 unique proteins were identified. These interactors were ranked using a Global Predicted Biological Score (Global PBS) from A to D, with ‘A’ representing the highest confidence of interaction (Fig. 5e, Supplementary Data 4). Notably, TgGSK3 was classified as an ‘A’ category interactor, suggesting TgGSK3 self-association. Additionally, interactions between TgGSK3 and the kinase SRPK, the Apical Cap protein AC8, as well as two hypothetical proteins (TGME49_228150 and TGME49_214090), already identified in proximity labeling experiments, were confirmed through this integrative analysis (compare Fig. 5b and e). To further assess the plausibility of direct physical interactions, we performed AlphaFold-Multimer predictions using AlphaFold3²⁷ for all candidate protein pairs identified by both BioID2 and Y2H. While this approach supported several candidate interactions (Supplementary Data 5), it did not detect high-confidence structural models for interactions between TgGSK3 and SRPK, AC8, TGME49_228150, or TGME49_214090. This limitation may reflect the transient or low-affinity nature of these associations, particularly in the case of kinase-substrate interactions, which are often difficult to capture with current structural prediction tools. Importantly, the majority of the identified TgGSK3’s interactors are indispensable for tachyzoite proliferation (Fig. 5f), as defined by genome-wide CRISPR-based fitness screens²³. This observation is consistent with the essential role of TgGSK3 in parasite viability and supports its functional integration into key signaling and regulatory networks in T. gondii.

The kinase-dead Y2H screen identified TgGSK3 as its own primary interaction hub, suggesting a mechanism of homo-dimerization or multimerization. This self-interacting ability has also been observed in the metazoan homolog GSK3-β, where it plays a pivotal role in activating various serine threonine kinases²⁸. In solution, however, the recombinant TgGSK3 expressed in insect cells predominantly exists as a monomer (Supplementary Fig. 6a), indicating that homo-oligomerization process does not occur spontaneously, but is instead dependent on external factors such as substrate binding, co-factors, interacting partners, or post-translational modifications. In this regard, during crystallization trials of TgGSK3 with LY2090314, an intriguing observation was made: alongside the standard crystal forms, a monoclinic crystal lattice emerged after several weeks, diffracting at lower resolution (3.0 Å) and containing four TgGSK3 subunits within the asymmetric unit. These four subunits can be reduced to two homodimers, interacting through non-crystallographic symmetry. In each dimer, TgGSK3 forms a face-to-face interaction (Fig. 5g), relying partly on the seed region identified in the yeast 2-hybrid screening, which spans most of the N-lobe. Additionally, the dimer is crosslinked by a disulfide bridge formed between the cysteine 213 of adjacent monomers (Fig. 5g; Supplementary Fig. 6B). This peculiar cysteine, located on the activation loop just two residues downstream of the phosphotyrosine 211, requires significant structural rearrangements to enable bond formation with the neighboring subunit when compared to the monomeric orthorhombic crystal structure of TgGSK3 (Supplementary Fig. 6b and c). Despite these structural rearrangements, the activation loop remains in a DFG “in” conformation due to the interaction with LY2090314. This trans-disulfide bridge could initially be considered a crystallization artifact. However, cysteine-mediated crosslinked kinase dimers are rare, with only a handful of crystal structures in the PDB available for comparison. Representative examples include PDB IDs: 1ZMW (MARK2, CAMK family), 2WNT (ribosomal protein S6 kinase, RSK family), 5NG0 (RIP2K, Tyrosine Kinase-Like [TKL] superfamily), 4CZT (CIPK23 from Arabidopsis thaliana, CBL-interacting serine/threonine-protein kinase), 4EQU (STK10, STE family), and 6VPI and 6VPJ (Aurora kinase A, part of the AGC-related family). Notably, the human Aurora kinase (6VPJ) stands out, as its disulfide-linked cysteine (C290) occupied an equivalent position as the cysteine forming the disulfide bond in TgGSK3 (Supplementary Fig. 6f and g), despite the low sequence conservation in the activation loop region (Supplementary Fig. 6e). Similarly, this cysteine is found two residues downstream of the activation loop phosphotyrosine (Y211) in GSK3 and two residues after a phosphothreonine in Aurora kinase (T288, Supplementary Fig. 6e). In their study, the authors demonstrated that the conserved cysteine residue (C290 in Aurora) plays a critical role in autophosphorylation, driving kinase pathway activation and potentially linking this process to redox state transitions during mitosis²⁹. While these findings may not directly translate to TgGSK3, given the distinct functional role of the two kinases, they highlight a broader role for this cysteine in regulating dimerization and activation through redox signaling. Together, the Y2H results and the monoclinic crystal structure suggest that the activation pathway of TgGSK3 in T. gondii relies on a homodimerization process, likely controlled by the conserved cysteine 213, a feature preserved across species.

Discussion

In this study, we report the identification of LY2090314 as a potent growth inhibitor of Toxoplasma gondii, showing remarkable potency at sub-micromolar concentrations, low cytotoxicity to host cells and promising broad-spectrum potential against apicomplexan pathogens, including Cryptosporidium parvum. Specifically, LY2090314 demonstrated activity against C. parvum with an EC₅₀ ranging from 160 to 286 nM, representing a more than 2000-fold improvement compared to paromomycin, a drug known for its anti-Cryptosporidium activity³⁰.

Using a forward genetic approach combining transcriptome sequencing with computational mutation discovery, we identified mutations in the TgGSK3 coding sequence of T. gondii that confer resistance to LY2090314. Structural studies, including the determination of the first X-ray crystal structure of LY2090314 bound to TgGSK3, complemented by functional validation using an in vitro kinase assay with purified components, confirmed that LY2090314 directly inhibits TgGSK3 enzymatic activity. Collectively, these findings represent gold-standard evidence in the field of target deconvolution for bioactive small molecules and provide unequivocal confirmation for target engagement.

Importantly, we identified a T133M substitution in TgGSK3 that confers resistance to LY2090314. This threonine residue is highly conserved across homologous enzymes, including the human GSK3, as well as orthologs from Cryptosporidium and multiple other Apicomplexan species. The high prevalence of the T133M mutation in our forward genetic screens, coupled with the significant resistance it conferred, suggests that this mutation could represent the primary mechanism of resistance in patients treated with LY2090314 or related chemotypes. These findings not only emphasize the need to develop next-generation inhibitors to circumvent resistance, but also provide a blueprint for the development of structurally robust compounds targeting resistant variants of TgGSK3.

Using a forward genetic approach, we identified several mutations conferring drug resistance, all of which localize within or near the small-molecule binding site of TgGSK3. Notably, no mutations were detected elsewhere that could modulate kinase activity through allosteric mechanisms. Converging evidence from yeast two-hybrid assays and crystallographic analyses revealed covalent dimerization of TgGSK3, mediated by a conserved cysteine residue within the activation loop. This intermolecular interaction potentially represents a broader regulatory mechanism conserved within a subset of protein kinases. Moreover, this dimerization mechanism, which parallels the redox-regulated dimerization of human Aurora kinase, suggests that TgGSK3 activation can be similarly modulated by redox signaling. While this hypothesis is conceptually appealing, the physiological relevance of this dimeric state in T. gondii remains to be established. Further biochemical validation, including targeted mutagenesis (e.g., Cys-to-Ser substitutions) and enzymatic assays on purified monomeric and dimeric species, will be necessary to clarify whether this covalent dimerization contributes to TgGSK3 activation and/or regulation in vivo.

TgGSK3 emerges as a critical kinase in T. gondii, validated through a combination of chemical genetics, conditional mutagenesis, and structural biology. While the Plasmodium falciparum ortholog PfGSK3 has been explored as a potential antimalarial target^{31,32,33,34,35}, TgGSK3 represents the first GSK3 ortholog in Apicomplexa for which both the drug-target relationship and atomic-resolution structure have been elucidated. Notably, the chemical scaffolds of the PfGSK3 inhibitors reported in these studies are structurally distinct from LY2090314, suggesting that LY2090314 represents a novel pharmacological class with anti-apicomplexan activity. Functional inactivation of PfGSK3β (PF3D7_0312400) leads to a moderate reduction in erythrocyte invasion and impaired gametocyte maturation, without affecting overall parasite viability during asexual blood stages. This contrasts with our findings in T. gondii, where TgGSK3 inhibition by LY2090314 or its conditional depletion results in profound growth arrest and abnormal daughter cell formation in both tachyzoite and bradyzoite stages, highlighting potential species-specific functions for GSK3 in Apicomplexa. The TgGSK3 protein is also predicted to be expressed in non-tachyzoite stages based on transcriptomic data (ToxoDB), though its essentiality during the enteroepithelial sexual stages in the definitive host remains to be determined. These functional comparisons suggest that while Apicomplexan GSK3 enzymes may share conserved roles in parasite development and host cell invasion, TgGSK3 likely fulfills additional lineage-specific functions, possibly through its interaction with apical complex components and cytoskeletal regulators, as revealed by our proximity labeling and yeast two-hybrid analyses.

From a structural perspective, comparative analysis of TgGSK3 with its human ortholog HsGSK3β reveals key differences at the ATP-binding site, particularly within the gatekeeper and hinge regions (Supplementary Fig. 2b). In TgGSK3, residues M127 and H129 correspond to leucine and tyrosine in HsGSK3β, respectively, and these substitutions lie within the inhibitor coordination interface as revealed by our 2.1 Å crystal structure with LY2090314. Similar strategies for achieving selectivity were previously explored in Plasmodium GSK3 by docking and homology modeling³¹, underscoring the potential of leveraging subtle structural divergences to design selective GSK3 inhibitors against Apicomplexan pathogens.

Collectively, our findings establish TgGSK3 as the molecular target of LY2090314 and elucidate its mechanism of inhibition, providing a strong rationale for the continued exploration of Apicomplexan GSK3 as a therapeutic target.

Methods

Parasite strains and human cell cultures

Human primary fibroblasts (HFFs, ATCC® CCL-171™) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen), 10 mM (4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid) (HEPES) buffer pH 7.2, 2 mM L-glutamine and 50 μg/ml penicillin and streptomycin (Invitrogen). Human ileocecal adenocarcinoma cells (HCT-8) cultured in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, penicillin (50 U/mL), and streptomycin (50 µg/mL). Cells were incubated at 37 °C with 5% CO₂ in humidified air. Toxoplasma strains used in this study and listed in Supplementary Data 1 were maintained in vitro by serial passage on monolayers of HFFs. Cultures were free of mycoplasma as determined by qualitative PCR.

Reagents

The compounds LY2090314 and Indirubin were purchased from TargetMol and Sigma-Aldrich, respectively.

The following primary antibodies were used in the immunofluorescence, and/or immunoblotting: rabbit anti-TgGAP45 (gift from Pr. Dominique Soldati), mouse anti-HA tag (Roche, RRID: AB_2314622), rabbit anti-HA Tag (Cell Signaling Technology, RRID: AB_1549585), rabbit anti-FLAG (Cell Signaling Technology, RRID: AB_2798687) and mouse anti-MYC clone 9B11 (RRID: AB_2148465). They were manufactured by Eurogentec and used for immunofluorescence and immunoblotting. Secondary immunofluorescent antibodies were coupled with Alexa Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific). Secondary antibodies used in Western blotting were conjugated to alkaline phosphatase (Promega).

Drug screening analysis

The primary screening was conducted using a curated library of 514 small molecules, each provided as a 1 mM stock solution in dimethyl sulfoxide (DMSO)¹⁸. Compounds were screened in triplicate at a final concentration of 5 µM with 0.5% DMSO. T. gondii RH strain expressing NanoLuc luciferase (NLuc) and Emerald GFP (EmGFP) (RH NLuc) was used to enable quantitative assessment of parasite burden via fluorescence and luminescence readouts. Percentage growth inhibition was calculated relative to the DMSO vehicle control (set to 100% growth) as described previously¹⁸. For each compound, a composite z-score was calculated using the formula: z-score = (% inhibition – mean) / standard deviation. DMSO-treated wells and pyrimethamine (positive control) were included on each plate as internal references. Parasite load was quantified by EmGFP fluorescence, while host cell viability was assessed in parallel by Hoechst staining. This dual-readout system enabled simultaneous evaluation of antiparasitic activity and cytotoxicity (Supplementary Data 1).

Measurement of EC₅₀ for T. gondii parasites and CC₅₀ determination

The in vitro inhibitory activity of small compounds on Toxoplasma gondii proliferation was assessed using the following protocol. A total of 2000 tachyzoites of the T. gondii RH strain expressing nanoluciferase (RH NLuc) were allowed to invade confluent human foreskin fibroblast (HFF) monolayers in a 96-well plate for 2 h. The inhibitor LY2090314, along with pyrimethamine (as a minimum signal control), were diluted in growth medium and added to the monolayers at various concentrations in triplicate (technical replicates), with DMSO-treated controls serving as maximum signal controls. The assay was conducted in a final volume of 100 μL.

After 48 h of incubation at 37 °C, the medium was removed and 50 μL of PBS was added to each well. The NanoLuc assays were performed using the Nano-Glo® Luciferase Assay System according to the manufacturer’s instructions (Promega). Lysis was achieved by adding 50 μL of Nano-Glo® Luciferase Assay Reagent containing a 1:50 dilution of Nano-Glo® Luciferase Assay Substrate. Following a 3-minute incubation, luminescence was measured using the CLARIOstar® plate reader (BMG Labtech). Bioluminescence values from uninfected host cells were used to determine the background signal.

EC₅₀ values were calculated using non-linear regression analysis of normalized data, assuming a sigmoidal dose-response curve. The EC₅₀ values for each compound represent the average of at least three independent biological replicates. The cytotoxicity of LY2090314 on HFF and ARPE-19 cells was evaluated after 72 h of incubation using the CellTox™ Green Cytotoxicity Assay and CellTiter-Blue® Reagent (Promega).

Measurement of EC₅₀ for C. parvum parasites and CC₅₀ determination for HCT-8

HCT-8 cells were grown to 80% confluency in white 96-well plates (Thermo Scientific Nunc MicroWell) and infected with freshly purified nLuc-mCherry-–expressing oocysts (multiplicity of infection (MOI), 0.5). LY2090314 and Indirubin stock solutions were prepared at 100 mM in DMSO. After 3 h, infected cell cultures were washed 3 times, and medium was replaced with LY2090314 or Indirubin derivate E804 at different concentrations and further incubated for 48 h. ¾ of the culture supernatant was removed from the wells (six replicates for each concentration), and 25 µL of Nano-Glo lysis buffer containing 1:50 of Nano-Glow substrate (Promega) was added to the wells. After 3 min of incubation, luminescence was measured with GloMax-Multi+ (Promega) and EC₅₀ was calculated using GraphPad Prism software from the dose-response inhibition curve. The cytotoxic concentration 50% (CC₅₀) of the compounds were tested at 48 h incubation using the MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, MTS, Promega).

Plasmids and primers

Oligonucleotides were ordered from Sigma-Aldrich. PCR amplifications were performed with KOD Xtreme™ Hot Start DNA Polymerase. Primers and plasmids used or generated in this study are listed in Supplementary Data 1.

The bicistronic vectors expressing the Cas9 genome editing enzyme and specific sgRNAs targeting the TgGSK3 coding sequence were constructed as described previously³⁶. Briefly, oligonucleotides TgGSK3^G54D-CRISPR-FWD and TgGSK3^G54D-CRISPR-REV, TgGSK3^H129D-CRISPR-FWD and TgGSK3^H129D-CRISPR-REV, and TgGSK3^T133M-CRISPR-FWD and TgGSK3^T133M-CRISPR-REV (Supplementary Data 1) were annealed and ligated into the pTOXO_Cas9-CRISPR plasmid to create vectors used for construction of T. gondii recombinant for TgGSK3^G54D, TgGSK3^H129D and TgGSK3^T133M, respectively.

To construct the vectors pLIC-TgGSK3-HF-DHFR, pLIC-TgGSK3-mAID-HA-DHFR, and pLIC-TgGSK3-BioID2-HA-HXGPRT the coding sequence of TgGSK3 was amplified using primers LICF-265330_F and LICR-265330_R with RH ku80 genomic DNA as the template. The PCR product was then cloned into the pLIC-HF-DHFR, pLIC-mAID-HA-DHFR, and pLIC-BioID2-HA-HXGPRT (GenBank: PQ679940) vectors, respectively, using the LIC cloning method as described by ref. ³⁷.

To generate the TgGSK3 conditional knock out (cKO) plasmid, pUC57Simple-LoxP-GSK3-LoxP-HXGPRT, the TgGSK3 5’UTR with a loxP site inserted 100 bp upstream of the TgGSK3 start codon, and a recodonized TgGSK3 cDNA-HA sequence, were DNA-synthesized by GenScript (GenBank: PQ181256) using plasmid pUC57Simple-LoxP-HXGPRT (Genbank: PQ154619) as vector backbone.

Vectors for recombinant expression of TgGSK3 (aa 21-385 and aa 46-385) in insect cell were codon optimized and synthetized by Genscript (GenBank: PQ846733 and PQ846732, respectively) using the pFastBac1 vector as backbone.

Toxoplasma transfection and generation of parasite lines

T. gondii strains were transfected using electroporation parameters established previously¹⁸. Stable integrants or recombinants were selected with 25 mg/ml mycophenolic acid and 50 mg/ml xanthine or 1 mM pyrimethamine, and cloned by limiting dilution.

For endogenous gene tagging in Toxoplasma, the RH ku80 strain was used as described³⁷. Briefly, ~20 μg of each construct was linearized within the region of homology. Linearized vectors pLIC-TgGSK3-HF and pLIC-TgGSK3-BioID2-HA-HXGPRT (EcoRV) were phenol-chloroform extracted and ethanol precipitated. Constructions were re-suspended in TlowE buffer (10 mM Tris-HCl [pH8.0], 0.1 mM EDTA) for transfection. Stable recombinants were selected with pyrimethamine or mycophenolic acid and xanthine, single-cloned by limiting dilution, and verified by IFA. The resulting strains are RH TgGSK3-HF and RH TgGSK3-BioID2-HA, respectively (Supplementary Data 1).

To generate the conditional TgGSK3 knock-out strain (RH DiCre TgGSK3), the plasmid pUC57Simple-LoxP-GSK3-LoxP-HXGPRT was linearized using NdeI and cotransfected with pTOXO_Cas9-CRISPR::sgTgGSK3^H129D into the RH DiCre strain²⁴. Recombinant parasites were selected 24 h post transfection by addition of 25 mg/mL mycophenolic acid and 50 mg/mL xanthine to culture medium. Resistant parasites were cloned, and successful integration at the TgGSK3 locus and absence of the endogenous sequenced were confirmed using primer pairs P1/P2 and P1/P3. Rapamycin-induced excision of the floxed TgGSK3 sequence was confirmed using primer pair P1/P4.

C. parvum transfection and generation of parasite lines

C. parvum INRAE and IOWA (Univ. of Arizona) strains were transfected using an AMAXA Nucleofector 4D device (Lonza) with plasmids generated by Wilke et al³⁸. and purchased from Addgene (pACT1:Cas9-GFP, U6:sgTK (Cat# 122852); Plasmid: pACT1:Cas9-GFP, U6:sgUPRT (Cat# 122853). For every transfection, 1.2 × 10⁸ purified C. parvum WT oocysts were suspended in 1 mL of 0,75% taurocholic acid suspension in PBS and incubated at 37 °C for ~45 minutes. The progress of excystation was checked under microscope and excysted sporozoites were washed in PBS. The parasites were then suspended in 95 µL of SE buffer (SF cell Line 4D-Nucleofector kit, Lonza) and mixed with 100 µg plasmids in a final volume of 100 µL before being electroporated in a nucleocuvette vessel (Lonza). Following the electroporation, 100 µL of PBS was immediately added and 100 µL of the suspension inoculated orally to each of the two GKO mice that had received 5 min earlier 100 µL of an 8% sodium bicarbonate buffer. The mice were submitted to paromomycin selection at 16 mg/mL in the drinking water from 24 h post infection. The two C. parvum strains (INRAE-nLuc-mCherry and IOWA-nLuc-mCherry) were verified for mCherry expression by IFA and Nluc activity (Supplementary Data 1).

Immunofluorescence microscopy

Cells cultured on coverslips were fixed in 3% formaldehyde for 20 minutes at room temperature, permeabilized with 0.1% (v/v) Triton X-100 for 15 minutes, and blocked in phosphate-buffered saline (PBS) containing 3% (w/v) bovine serum albumin (BSA). Samples were incubated for 1 h with primary antibodies (GAP45), followed by secondary antibodies conjugated to Alexa Fluor 350, 488 or 594 (Molecular Probes) to detect intracellular parasites. Nuclei were stained with Hoechst 33258 for 10 minutes at room temperature. Coverslips were mounted on glass slides using Mowiol mounting medium, and 0.25 μm Z-stack images were acquired with an Axio Imager M2 fluorescence microscope (Carl Zeiss, Inc.). Images were processed using Icy 2.0 software (icy.bioimageanalysis.org) with the EpiDEMIC plugin for blind deconvolution of each channel separately. Maximum projections of deconvoluted stack images are presented.

Western blot

Immunoblot analysis of protein was performed as described in ref. ¹⁸. Briefly, ~10⁷ cells were lysed in 50 µL lysis buffer (10 mM Tris-HCl, pH6.8, 0.5% SDS [v/v], 10% glycerol [v/v], 1 mM EDTA and protease inhibitors cocktail) and sonicated. The protein extracts were separated by SDS-PAGE, and transferred to a PolyVinyliDene Fluoride membrane (PVDF; immobilon-P, Millipore) by liquid transfer. Membranes were then blocked with PBS buffer containing 0.01% Tween 20 (v/v) and 5% nonfat dry milk. Appropriate primary antibodies diluted in PBS containing 0.03% Tween 20 (v/v) were used to probe the membrane. Primary antibodies were detected using alkaline phosphatase conjugated secondary antibodies and the nitro blue tetrazolium (NBT)/5-Bromo-4-chloro-3-indolyl phosphate (BCIP) revelation (Amresco) or enhanced chemiluminescence system (Thermo Fisher Scientific).

Plaque assays

Parasite growth was assessed following the protocol described by ref. ²². Briefly, freshly egressed parasites were inoculated onto a confluent monolayer of HFFs and cultured for 7 days with or without the indicated compounds. Cells were then fixed and stained with Coomassie blue staining solution (0.1% Coomassie R-250 in 40% ethanol and 10% acetic acid). Plaque sizes, when present, were measured using ZEN 2 lite software (Carl Zeiss Inc.) or Icy 2.0 software (icy.bioimageanalysis.org) with the Magic Wand Tool to select plaques.

Toxoplasma gondii random mutagenesis

Parasites were chemically mutagenized following the protocol described by ref. ²², with the following modifications. ~10⁷ tachyzoites (RH strain) growing intracellularly in HFF cells within a T25 flask were incubated at 37 °C for 4 h in 0.1% Fetal Bovine Serum (FBS) DMEM growth medium containing either 2.5 mM ethyl methane sulphonate (EMS) or the appropriate vehicle controls. Post-mutagen exposure, parasites were washed three times with PBS. The mutagenized population was then allowed to recover in a fresh T25 flask containing an HFF monolayer without the drug for 3–5 days. Subsequently, released tachyzoites were inoculated into fresh cell monolayers in a medium containing 600 nM LY2090314 and incubated until viable extracellular tachyzoites emerged 8–10 days later. Surviving parasites were passaged once more under continued LY2090314 treatment and cloned by limiting dilution. Three cloned mutants were isolated from each of the 8 independent mutagenesis experiments, resulting in unique SNV pools for each flask.

RNA-seq, sequence alignment, and variant calling

For each biological assay, a T175 flask containing a confluent monolayer of HFF was infected with RH wild-type or LY2090314-resistant lines. Total RNA was extracted and purified using TRIzol (Invitrogen, Carlsbad, CA, USA) and RNeasy Plus Mini Kit (Qiagen). RNA quantity and quality were measured using NanoDrop 2000 (Thermo Scientific). RNA sequencing was performed as previously described by Bellini et al²²., following standard Illumina protocols, by Novogene (Munich, Germany). Briefly, RNA quantity, integrity, and purity were determined using the Agilent 5400 Fragment Analyzer System (Agilent Technologies, Palo Alto, California, USA). The integrity values or RIN ranged from 9.1 to 10 for all samples, which was considered sufficient. Messenger RNAs (mRNA) were purified from total RNA using poly-T oligo-attached magnetic beads. After fragmentation, the first strand cDNA was synthesized using random hexamer primers. For directional libraries, the second strand cDNA was synthesized using dUTP, instead of dTTP. The directional library was ready after end repair, A-tailing, adapter ligation, size selection, USER enzyme digestion, amplification, and purification. The library was checked with Qubit and real-time PCR for quantification and bioanalyzer for size distribution detection. Quantified libraries were pooled and sequenced on Illumina platforms, according to effective library concentration and data amount. The samples were sequenced using the Illumina NovaSeq platform, employing both non-stranded (for variant calling analysis) and strand-specific sequencing (for gene expression analysis) with 2 × 150 bp reads and generated ~40 million paired-end reads for each sample.

For variant calling analysis (non-stranded libraries), the RNA-Seq reads (FASTQ files) were processed and analyzed using the Lasergene Genomics Suite version 15 (DNASTAR, Madison, WI, USA) using default parameters. The paired-end reads were uploaded onto the SeqMan NGen (version 17, DNASTAR. Madison, WI, USA) platform for reference-based assembly and variant calling using the Toxoplasma Type I GT1 strain (ToxoDB-52, GT1 genome) as a reference template. The ArrayStar module (version 17, DNASTAR. Madison, WI, USA) was used for normalization, variant detection, and statistical analysis of uniquely mapped paired-end reads using the default parameters. Variant calls were filtered to select variants in coding regions with the following criteria: variant depth ≥ 30, Qcall ≥ 60, and absence in the parental wild-type strain (Supplementary Data 2). SNVs, insertions, and deletions in regulatory or intergenic regions were filtered out as they are unlikely to contribute to drug resistance. Mutations were plotted on a Circos plot using Circa (OMGenomics.com). The Illumina RNA-seq dataset generated during this study is available at National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO): GSE286338.

Bradyzoite differentiation and drug treatment assays

Differentiation of tachyzoites into bradyzoites was induced by CO₂ depletion at physiological pH (7.4) using HFF as host cells. HFF monolayers were maintained in CO₂ Independent Medium (Gibco, Cat# 18045-088) supplemented with 5% FBS, 2mM L-glutamine, and 50 μg/mL penicillin–streptomycin (Invitrogen). For stage conversion, we employed the ME49 pGRA1-dsRed2.0 pBAG1-mNeonGreen reporter strain³⁹, which constitutively expresses the red fluorescent protein (RFP) dsRed2.0 under the control of the tachyzoite-specific GRA1 promoter and expresses mNeonGreen (mNG) from the bradyzoite-specific BAG1 promoter. Infected cultures were incubated at 37°C under ambient CO₂ conditions to promote spontaneous differentiation. At 24 h post-infection (hpi), infected monolayers were washed with PBS to remove extracellular parasites, and the medium was replaced. Cultures were subsequently maintained by refreshing the medium every 48 h and washing with PBS once per week. After 14 days of differentiation in CO₂ Independent Medium under ambient CO₂, monolayers were trypsinized, and the resulting cell suspensions were resuspended in Hank’s Balanced Salt Solution (HBSS) supplemented with 5% FBS. mNeonGreen-positive cysts were isolated by fluorescence-activated cell sorting (FACS) using a CytoFLEX SRT Cell Sorter (Beckman Coulter), and 200 sorted cysts were seeded per well in a 24-well plate containing fresh CO₂-Independent Medium (Supplementary Fig. 1f-g).

Twenty-four h post-sorting, cultures were treated with either DMSO (vehicle control), 2 µM pyrimethamine, or 600 nM LY2090314. Following 72 h of incubation under bradyzoite-inducing conditions, cells were fixed in 4% paraformaldehyde and analyzed by immunofluorescence microscopy.

T. gondii genome editing

Targeted genome modifications were performed using the CRISPR/Cas9 system as described previously¹⁸. The recombinant parasites harboring allelic replacement for TgGSK3^G54D, TgGSK3^H129D, and TgGSK3^T133M were generated by electroporation of the T. gondii RH NLuc strain with pTOXO_Cas9-CRISPR vectors targeting the TgGSK3 coding sequence (pTOXO_Cas9-CRISPR::sgTgGSK3^G54D, pTOXO_Cas9-CRISPR::sgTgGSK3^H129D, and pTOXO_Cas9-CRISPR::sgTgGSK3^T133M) and their respective donor single-stranded oligo DNA nucleotides (ssODNs) carrying respective nucleotide substitutions (TgGSK3G54D_donor, TgGSK3H129D_donor, and TgGSK3T133M_donor; Supplementary Data 1) for homology directed repair. Recombinant parasites were selected with 600 nM LY2090314, as described previously in ref. ¹⁸ prior to subcloning by limited dilution, and allelic replacement was verified by sequencing of T. gondii GSK3 genomic DNA.

Targeted nanopore sequencing

Parasites were chemically mutagenized as described above. ~3×10⁷ tachyzoites (RH strain) growing intracellularly in HFF cells were incubated at 37 °C for 4 h in 0.1% Fetal Bovine Serum (FBS) DMEM growth medium containing either 2.5 mM ethyl methane sulphonate (EMS) or the appropriate vehicle controls. Post-mutagen exposure, parasites were washed three times with PBS. The mutagenized population was then allowed to recover in a fresh T25 flask containing an HFF monolayer without the drug for 3–5 days. Subsequently, released tachyzoites were inoculated into fresh cell monolayers in a medium containing 600 nM LY2090314 and incubated until viable extracellular tachyzoites emerged 8–10 days later. The resistant parasites were harvested and stored at -80 °C.

DNA was extracted from tachyzoites using the Blood & Cell Culture DNA Midi kit (Qiagen, 13343) and the Genomic-tip 100/G (Qiagen, 102343). Purified and unsheared high-molecular weight genomic DNA was resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and stored at 4 °C until use. DNA was quantified using the Qubit fluorometer (Thermo) immediately before performing the assay.

Guide RNAs were assembled as a duplex from synthetic Alt-R® CRISPR-Cas9 crRNA, (IDT, custom designed) and Alt-R® CRISPR-Cas9 tracrRNA (IDT, 1072532). Sequences are provided in Supplementary Data 1. The crRNAs were designed using CHOPCHOP (chopchop.cbu.uib.no) design tool and selected for the highest predicted on-target performance with minimal significant secondary structure and off-target activity. The gRNA duplex was designed to introduce cuts on complementary strands flanking the region of interest. The gRNAs were designed to flank the TGGT1_265330 coding region; the target size between gRNAs was 7410–7773 kb.

Prior to guide RNA assembly, all crRNAs were pooled into an equimolar mix, with a total concentration of 100 µM. The crRNA mix and tracrRNA were then combined in nuclease free duplex buffer (IDT, 11-01-03-01) such that the tracrRNA concentration and total crRNA concentration were both 10 µM. The gRNA duplexes were formed by denaturation for 5 minutes at 95 °C, then allowed to cool to room temp for 5 minutes on a benchtop. Ribonucleoprotein complexes (RNPs) were constructed by combining 100 pmol of gRNA duplexes with 49.6 pmol of HiFi Cas9 Nuclease V3 (IDT, 1081060) in reaction buffer (RB) from the Oxford Nanopore Technologies (ONT) Cas9 Sequencing Kit (SQK-CS9109) at a final volume of 100 μL, incubated 30 minutes at room temperature, then stored at 4 °C until use, up to a week.

Five µg of high-molecular weight genomic DNA was dephosphorylated in 30 µL RB and 3 µL of Phosphatase (ONT, SQK-CS9109) for 10 min at 37 °C, followed by heating for 2 minutes at 80 °C for enzyme inactivation. After allowing the sample to return to room temperature, 10 µL of the pre-assembled Cas9/gRNA complexes was added to the sample. In the same tube, 1 µL of 10 mM dATP and 1 µL of Taq DNA polymerase (ONT, SQK-CS9109) were added for cleaving of target DNA and dA-tailing of DNA ends. The sample was then incubated at 37 °C for 15 minutes for Cas9 cleavage followed by 5 minutes at 72 °C for dA-tailing. Sequencing adaptors (AMX, ONT Cas9 Sequencing Kit) were ligated to DNA ends using T4 Ligase and the ligation buffer (LNB). Prior to purification, SPRI Dilution Buffer (SDB) was added to the sample. The purification step involved the addition of 0.3X AMPure XP beads (Beckman Coulter, A63881), followed by two washes on a magnetic rack using long fragment buffer (LFB) to ensure selective enrichment of DNA fragments ≥3 kilobase pairs. DNA library was eluted in 25 µL of elution buffer (EB, ONT Cas9 Sequencing Kit). Sequencing libraries were prepared by adding the following to the eluate: 75 µL sequencing buffer (SQB,) and 51 µL loading beads (LB, ONT Cas9 Sequencing Kit).

Samples were run on a MinION (ver 9.4.1) flow cell using the MK1B. Sequencing runs were operated using the MinKNOW software (v24.06.16).

Basecalling was performed using GUPPY (Version 6.4.6) to generate FASTQ sequencing reads. Reads were aligned to the T. gondii reference genome (ToxoDB-67, GT1 genome) using Minimap2 (v2.28). Alignment files were converted to bam files and sorted using samtools.

Recombinant expression of TgGSK3 using baculovirus

Bacmid cloning steps and baculovirus generation were performed using EMBacY baculovirus (gifted by I. Berger), which contains a yellow fluorescent protein reporter gene in the virus backbone. The established standard cloning and transfection protocols set up within the EMBL Grenoble eukaryotic expression facility were used. Although baculovirus synthesis (V0) and amplification (to V1) were performed with SF21 cells cultured in SF900 III medium (Life Technologies), large-scale expression cultures were performed with Hi-5 cells cultured in Express-Five medium (Life Technologies) and infected with 0.5% (v/v) of generation 2 (V1) baculovirus suspensions and harvested 72 h after infection.

TgGSK3 expression and purification

Eight cell pellets, each from a 250 mL Hi5 culture, were resuspended in 120 mL of lysis buffer [50 mM tris (pH 8.0), 300 mM NaCl and 2 mM β-mercaptoethanol (β-ME)] in the presence of an anti-protease cocktail (Complete EDTA-free, Roche) and 4 μl of benzonase (Merck Millipore, 70746). Lysis was carried out on ice using sonication for 4 minutes (30-s on/ 30-s off, 45% amplitude). Clarification was then achieved by centrifugation at 12,000 g for 1 h at 4 °C. Following this, 5% glycerol and 20 mM imidazole were added and the mixture was incubated with 6 ml of Ni–nitrilotriacetic acid (NTA) resin (QIAGEN) at 4 °C for 30 min using a stirring magnet. All subsequent purification steps were conducted at room temperature. Once pulled into the column, the resin was washed twice with 10 cv of lysis buffer containing 20 mM imidazole and 5% glycerol with an intermediate wash using 1 M NaCl. Elution was performed by increasing lysis buffer imidazole concentration up to 300 mM. Eluted fractions were pooled based on SDS-PAGE analysis and passed through a pre-equilibrated [in 100 mM NaCl, 50 mM tris (pH 7.5), 1 mM β-ME, and 5% glycerol] heparin column connected to an AKTA Pure system. TgGSK3 does not bind to the column, but many contaminents are retained. Last, the recovered heparin flow through was concentrated and injected onto a SUPERDEX 200 increase 10/300GL (GE Healthcare) column operating in 300 mM NaCl, 50 mM Tris pH8, 1 mM β-ME and 1% glycerol, with elution monitored at 280 nm. Peak fractions were concentrated using a 30-kDa Amicon concentrator, then frozen in liquid nitrogen and stored long-term at −80 °C.

Size exclusion chromatography coupled to laser light scattering (SEC-MALLS)

TgGSK3 (amino acids 21-385) SEC-MALLS was performed on a S200 10/300 GL increase column (GE Healthcare) running in a buffer system containing 20 mM tris (pH 7.5), 300 mM NaCl, and 1 mM β-ME on an OMNISEC (Malvern) system equipped with RALS, LALS, UV RI and Viscosimeter detectors. Injections of 50 µl were performed using protein samples concentrated at a minimum of 2 mg/mL, and a constant flow rate of 0.5 mL/min was used. Data treatment and mass determination were performed using the OMNISEC software.

Microscale thermophoresis

Microscale thermophoresis (MST) measurements were performed using a NanoTemper Monolith NT.115 Green/Red instrument. 200 nM WT and mutated TgGSK3 proteins were added to 100 nM dye solution from the Monolith His-Tag Labeling Kit RED-tris-NTA second generation (NanoTemper Technologies) both diluted in 50 mM NaCl, 20 mM Tris HCl pH8, 1 mM MgCl₂ and 0.05% Tween 200. After a 30-minute incubation at room temperature, the samples were centrifuged to clear residual compound. In parallel, a series of 14 twofold dilutions of LY2090314 starting from 5 μM were prepared in pure DMSO. Finally, the labeled protein and drug dilution mixture (v/v) were loaded into premium capillaries (NanoTemper Technologies) for measurement using the instrument’s recommended settings of 40% light-emitting diode power and 40% MST power.

Kinase activity assays

Serial dilution of LY2090314 were prepared from 500 μM to 30 nM in pure DMSO. One microliter of this serial dilution and pure DMSO for control was added to 39 μL of 150 nM TgGSK3, 25 μM ATP and 10 μM GSM peptide substrate (RRRPASVPPSPSLSRHS(pS)HQRR; synthetized by EMD Millipore Corporation), within 50 mM NaCl, 50 mM tris (pH 7.5), 1 mM β-ME, 1% BSA and 5 mM MgCl₂. The reaction mix was kept for 3 h at 30 °C in a thermocycler. The final ATP content was determined using the Kinase-Glo Plus assay (Promega) according to the manufacturer’s protocol and luminescence titrations were measured on the CLARIOstar (BMG Labtech) with a 10-second acquisition time within white 96-well plates. Raw luminescence data were normalized for each condition, with the lowest value (control with 100% DMSO) set to represent 100% kinase activity. All titrations were performed in triplicate, with the entire experiment repeated three times for consistency. Apparent IC₅₀ determination was realized through a four-parameter nonlinear inhibition curve fitting in GraphPad Prism.

Crystallization with LY2090314

5 mg/ml of TgGSK3 (aa 46-385) was incubated with 1 mM LY2090314 for 5 minutes at room temperature and centrifuge to eliminate compound aggregate prior injection onto an S200 columns running into 300 mM NaCl, 50 mM Tris pH8, 1 mM β-ME and 1% glycerol. The eluted protein fractions were pooled and concentrated to a final concentration of 20 mg/ml. Crystallization was performed using the hanging drop vapor diffusion method with GSK3/LY2090314 (1:1) with 1 M sodium malonate pH 6. Crystals appearing generally after few days were harvested using Hampton nylon loops, cryoprotected in 6 M sodium malonate and flash-frozen in liquid nitrogen. With a similar approach, the second construct yielding the monoclinic crystal system (aa 20 to 385) was also prepared with LY2090314 and hanging drops were setup in 5% MPD, 9% PEG 6000 and 0.1 M Tris pH 7.5. Crystals only started growing after several weeks with these conditions. Cryoprotection of these crystals was performed with precipitant supplemented by 20 % glycerol.

Data collection and structure determination

X-ray diffraction data for TgGSK3/LY2090314 crystals were collected by the autonomous European Synchrotron Radiation Facility (ESRF) beamline MASSIF-1^40,41 using automatic protocols for the location and optimal centering of crystals⁴². In all cases, diffraction was performed at 100 K. Data reduction was per- formed using XDS⁴³ while amplitude scaling/merging was performed by Xscale. The first molecular replacement solution for the orthorhombic crystal was obtained with Phaser⁴⁴ using the crystal AlphaFold model of TgGSK3 [AlphaFold/Uniprot A0A125YY75 entry] as a template. The initial phasing solution was then improved through cycles of manual adjustment in Coot⁴⁵, automated building in phenix autobuild⁴⁶ and refined using Refmac5 or phenix refine. Final pdb model corrections were performed using the pdb-redo server⁴⁷. A similar approach was also used for the monoclinic crystal though the initial orthorhombic crystal structure of TgGSK3 was used as molecular replacement search model.

Yeast two-hybrid analysis

Yeast two-hybrid screening was performed by Hybrigenics Services, S.A.S., Evry, France (http://www.hybrigenics-services.com). The coding sequence for TgGSK3^K76H (aa 1-394) was PCR-amplified from plasmid pUC57Simple-TgGSK3^K76H (GenBank: PQ181257) and cloned into pB29 vector as an N-terminal fusion to LexA (TgGSK3^K76H-LexA). The construct was checked by sequencing the entire insert and used as a bait to screen a random-primed Toxoplasma gondii wild-type RH strain cDNA library constructed into pP6 vector. pB29 and pP6 derive from the original pBTM116^48,49 and pGADGH⁵⁰ plasmids, respectively. Parasite RNA for the Toxoplasma gondii Y2H library was generated by Drs. Sherri Huang and Bill Sullivan at the Indiana University School of Medicine. 47.4 million clones ( ~ 5-fold the complexity of the library) were screened using a mating approach with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, matα) and L40ΔGal4 (MATa) yeast strains as previously described⁵¹. 246 His⁺ colonies were selected on a medium lacking tryptophan, leucine and histidine, and supplemented with 10 mM 3-aminotriazole to handle bait autoactivation. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5’ and 3’ junctions. The resulting sequences were used to identify the corresponding interacting proteins in the GenBank database (NCBI) using a fully automated procedure. A confidence score (PBS, for Predicted Biological Score) was attributed to each interaction as previously described⁵².

The PBS relies on two different levels of analysis. Firstly, a local score takes into account the redundancy and independency of prey fragments, as well as the distribution of reading frames and stop codons in overlapping fragments. Secondly, a global score takes into account the interactions found in all the screens performed at Hybrigenics using the same library. This global score represents the probability of an interaction being nonspecific. For practical use, the scores were divided into four categories, from A (highest confidence) to D (lowest confidence). A fifth category (E) specifically flags interactions involving highly connected prey domains previously found several times in screens performed on libraries derived from the same organism. Finally, several of these highly connected domains have been confirmed as false-positives of the technique and are now tagged as F. The PBS scores have been shown to positively correlate with the biological significance of interactions^53,54.

Proximity labeling of intracellular TgGSK3-BioID2-HA strain and mass spectrometry-based proteomics

Freshly egressed parasites expressing TgGSK3-BioID2-HA (RH TgGSK3-BioID2-HA strain) were used to infect confluent HFF monolayers in two 175 cm² flasks per condition ( ~ 10⁷ parasites per flask). The parental RH ku80 strain was used as a control. The parasites invaded and replicated in host cells for 24 h in the presence or absence of 150 µM biotin (Sigma-Aldrich, B4639). Parasites invaded and replicated in host cells for 24 h in the presence or absence of 150 µM biotin (Sigma-Aldrich, B4639). Following incubation, parasites were harvested, washed three times with 50 mL of cold PBS, and stored at -80 °C until further processing. Experimental duplicates were performed for TgGSK3-BioID2-HA samples.

Parasites were lysed in 400 µL radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100) supplemented with complete protease inhibitor cocktail (Roche) and incubated on ice for 30 minutes. Samples were sonicated (Diagenode Bioruptor, 5 cycles of 15 s ON/30 s OFF), yielding a total protein content of 2.1 ± 0.3 mg. Insoluble debris was removed by centrifugation (14,000 × g, 30 minutes), and the supernatants were incubated with 200 µL of magnetic streptavidin beads (Bio-Adembeads, 300 nm) pre-equilibrated twice in RIPA buffer. Incubation was performed for 2 h at room temperature with gentle agitation (5 rpm).

Following incubation, the beads were washed sequentially: twice with 1 mL RIPA buffer containing 1 mM EDTA (cold; 10 minutes), once with 1 mL 1 M KCl (at room temperature; 10 minutes), once with 1 mL 0.1 M Na₂CO₃ (cold; 1 minute), once with 1 mL 2 M urea in 10 mM Tris-HCl (pH 8.0; at room temperature, 1 minute), and twice with 1 mL RIPA buffer (cold; 10 minutes). The supernatant was discarded, and the beads were snap-frozen in liquid nitrogen and stored at -80 °C. Proteins were digested on beads using modified trypsin (Promega, sequencing grade), as described in ref. ⁵⁵. The resulting peptides were analyzed by online nanoliquid chromatography coupled to MS/MS (Ultimate 3000 RSLCnano and Q-Exactive HF, Thermo Fisher Scientific). For this purpose, the peptides were sampled on a precolumn (300 μm × 5 mm PepMap C18, Thermo Scientific) and separated in a 75 μm × 250 mm C18 column (Aurora Generation 3, 1.7μm, IonOpticks) using a 120 min acetonitrile gradient. The MS and MS/MS data were acquired by Xcalibur version 2.9 (Thermo Fisher Scientific). Peptides and proteins were identified by Mascot (version 2.8.3, Matrix Science) through concomitant searches against the Toxoplasma gondii database (ME49 taxonomy, version 58 downloaded from ToxoDB), the Uniprot_database (Homo sapiens taxonomy, 202402 version), the sequence of TgGSK3-BioID2-HA, and a homemade database containing the sequences of classical contaminant proteins found in proteomic analyses (human keratins, trypsin…). Trypsin/P was chosen as the enzyme and two missed cleavages were allowed. Precursor and fragment mass error tolerances were set at respectively at 10 and 20 ppm. Peptide modifications allowed during the search were: Carbamidomethyl (C, fixed), Acetyl (Protein N-term, variable) and Oxidation (M, variable). The Proline software (⁵⁶, version 2.3.1) was used for the compilation, grouping, and filtering of the results (conservation of rank 1 peptides, peptide length ≥6 amino acids, false discovery rate of peptide-spectrum-match identifications <1%⁵⁷, and minimum of one specific peptide per identified protein group). Proline was then used to perform a MS1 label-free quantification of the identified protein groups based on razor and specific peptides. Protein abundances were then compared between parasites expressing TgGSK3-BioID2-HA and parasites that do not express any BioID2 fusion protein that were incubated with 150 µM biotin for 24 h. For this, only proteins identified in the Toxoplasma gondii database were considered, abundances were log transformed and median normalized, and missing values were imputed by the mean of the first percentile values of each sample. Proteins were considered proximal to TgGSK3 if they were enriched at least 5 times in both TgGSK3-BioID2-HA replicates compared to mock control.

Enrichment analysis

Sets of gene ontology (GO) terms associated with proteins identified through proximity labeling (TgGSK3-BioID2-HA) and yeast two-hybrid screening using TgGSK3^K76E as bait, along with the background proteome (all proteins quantified in each experiment), were retrieved from ToxoDB.org. GO terms were analyzed under the category “Molecular Function” with computed evidence, applying a p value cutoff of 0.05. Enrichment analysis was performed by comparing the GO terms identified in the proximity labeling and yeast two-hybrid datasets against those found in the background proteome. Statistical significance for enrichment was determined using a hypergeometric test, yielding p values that represent the likelihood of observed enrichments occurring by chance.

Analysis of alphafold-multimer predictions

AlphaFold-Multimer structure predictions were analyzed using a custom Python script based on the AlphaPulldown framework⁵⁸, to extract interface features. For each predicted protein complex (provided as a.zip archive), the script parsed the model structure (.cif) and confidence metrics (.json), including the inter-protein predicted TM-score (iPTM). Chain–chain interfaces were identified based on a 5 Å distance cutoff between atoms. Only interactions with iPTM ≥0.6 were retained for further analysis. For each interface, residues from chain B (designated as the prey) involved in inter-chain contacts were extracted along with ±5 flanking residues. The resulting sequences were compiled and exported in tabular format for downstream analyses (Supplementary Data 5).

Bioinformatic tools

Venn diagram⁵⁹.

RAWGraphs Visualization Platform⁶⁰.

Clustal Omega, iTOL⁶¹.

CLC Sequence Viewer (QIAGEN).

DNAStar Lasergene v15 (DNASTAR, Madison, WI, USA).

All models were depicted using UCSF ChimeraX⁶².

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. pUC57Simple-LoxP-HXGPRT: Genbank PQ154619 pUC57Simple-LoxP-GSK3-LoxP-HXGPRT: Genbank PQ181256 (PQ181256) pLIC-BioID2-HA-HXGPRT: GenBank PQ679940 (PQ679940) pUC57Simple-TgGSK3^K76H: GenBank PQ181257 (PQ181257) TgGSK3_aa21-385_cter6His_pFastBac1: Genbank PQ846733 (PQ846733) TgGSK3_aa46-385_cter6His_pFastBac1: Genbank PQ846732 (PQ846732) The Illumina RNA Sequencing data generated in this study have been deposited in the GEO Datasets under accession number GSE286338 The coordinates and structure factors for the TgGSK3/ LY2090314 structures have been deposited in the PDB with the accession number 9HVX and 9HW6. (https://www.rcsb.org/structure/9HVX and https://www.rcsb.org/structure/9HW6). Please note that residue numbering is offset by 21 amino acids due to the N-terminal truncation of the crystallized constructs. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE⁶³ partner repository with the dataset identifier PXD059579 (https://www.ebi.ac.uk/pride/archive/projects/PXD059579). Source data are provided with this paper.

References

De Rycker, M., Baragaña, B., Duce, S. L. & Gilbert, I. H. Challenges and recent progress in drug discovery for tropical diseases. Nature 559, 498–506 (2018).
Article ADS PubMed PubMed Central Google Scholar
World malaria report. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023 (2023).
Djurković-Djaković, O., Dupouy-Camet, J., Van Der Giessen, J. & Dubey, J. P. Toxoplasmosis: overview from a One Health perspective. Food Waterborne Parasitol. 15, e00054 (2019).
Article PubMed PubMed Central Google Scholar
Montoya, J. G. & Liesenfeld, O. Toxoplasmosis. Lancet 363, 1965–1976 (2004).
Article CAS PubMed Google Scholar
Glasner, P. D. et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am. J. Ophthalmol. 114, 136–144 (1992).
Article CAS PubMed Google Scholar
Bossi, P. et al. Severe acute disseminated toxoplasmosis acquired by an immunocompetent patient in French Guiana. Scand. J. Infect. Dis. 34, 311–314 (2002).
Article PubMed Google Scholar
Carme, B. et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J. Clin. Microbiol. 40, 4037–4044 (2002).
Article CAS PubMed PubMed Central Google Scholar
Demar, M. et al. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. Clin. Infect. Dis. 45, e88–e95 (2007).
Article PubMed Google Scholar
Demar, M. et al. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin. Microbiol. Infect. 18, E221–E231 (2012).
Article CAS PubMed Google Scholar
Leroy, J. et al. Severe toxoplasmosis imported from tropical Africa in immunocompetent patients: a case series. Travel Med. Infect. Dis. 35, 101509 (2020).
Article PubMed Google Scholar
Galal, L. et al. Toxoplasma and Africa: one parasite, two opposite population structures. Trends Parasitol. 34, 140–154 (2018).
Article PubMed Google Scholar
Carme, B., Demar, M., Ajzenberg, D. & Dardé, M. L. Severe acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French Guiana. Emerg. Infect. Dis. 15, 656–658 (2009).
Article PubMed PubMed Central Google Scholar
Mercier, A. et al. Additional haplogroups of Toxoplasma gondii out of Africa: population structure and mouse-virulence of strains from Gabon. PLoS Negl. Trop. Dis. 4, e876 (2010).
Article PubMed PubMed Central Google Scholar
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O. & Montoya, J. G. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin. Microbiol Rev. 31, e00057–17 (2018).
Article CAS PubMed PubMed Central Google Scholar
Gray, J. E. et al. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest N. Drugs 33, 1187–1196 (2015).
Article CAS Google Scholar
Rizzieri, D. A. et al. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk. Lymphoma 57, 1800–1806 (2016).
Article CAS PubMed Google Scholar
Walz, A. et al. Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer. Clin. Cancer Res. 23, 1891–1897 (2017).
Article CAS PubMed PubMed Central Google Scholar
Swale, C. et al. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. Sci. Transl. Med. 14, eabn3231 (2022).
Article CAS PubMed Google Scholar
Robert, M. G. et al. Uncovering biomarkers for chronic toxoplasmosis detection highlights alternative pathways shaping parasite dormancy. EMBO Mol. Med 17, 1686–1715 (2025).
Article CAS PubMed PubMed Central Google Scholar
Dard, C. et al. A brain cyst load-associated antigen is a Toxoplasma gondii biomarker for serodetection of persistent parasites and chronic infection. BMC Biol. 19, 25 (2021).
Article CAS PubMed PubMed Central Google Scholar
Arciniegas Ruiz, S. M. & Eldar-Finkelman, H. Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A Decade Onward. Front. Mol. Neurosci. 14, 792364 (2022).
Article PubMed PubMed Central Google Scholar
Bellini, V. et al. Target identification of an antimalarial oxaborole identifies AN13762 as an alternative chemotype for targeting CPSF3 in apicomplexan parasites. iScience 23, 101871 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Sidik, S. M. et al. A genome-wide CRISPR Screen in toxoplasma identifies essential apicomplexan genes. Cell 166, 1423–1435 (2016).
Article CAS PubMed PubMed Central Google Scholar
Hunt, A. et al. Differential requirements for cyclase-associated protein (CAP) in actin-dependent processes of Toxoplasma gondii. eLife 8, e50598 (2019).
Article CAS PubMed PubMed Central Google Scholar
Roumégous, C. et al. Identification of new components of the basal pole of Toxoplasma gondii provides novel insights into its molecular organization and functions. Front. Cell. Infect. Microbiol. 12, 1010038 (2022).
Article PubMed PubMed Central Google Scholar
Menolfi, D. & Zha, S. A. T. M. ATR and DNA-PKcs kinases—the lessons from the mouse models: inhibition ≠ deletion. Cell Biosci. 10, 8 (2020).
Article PubMed PubMed Central Google Scholar
Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).
Article ADS CAS PubMed PubMed Central Google Scholar
Oliver, A. W., Knapp, S. & Pearl, L. H. Activation segment exchange: a common mechanism of kinase autophosphorylation? Trends Biochem.Sci. 32, 351–356 (2007).
Article CAS PubMed Google Scholar
Lim, D. C. et al. Redox priming promotes Aurora A activation during mitosis. Sci. Signal. 13, eabb6707 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rossignol, J.-F. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp. Parasitol. 124, 45–53 (2010).
Article PubMed Google Scholar
Masch, A. & Kunick, C. Selective inhibitors of Plasmodium falciparum glycogen synthase-3 (PfGSK-3): new antimalarial agents? Biochim. et. Biophys. Acta (BBA) - Proteins Proteom. 1854, 1644–1649 (2015).
Article CAS Google Scholar
Alder, A. et al. Functional inactivation of Plasmodium falciparum glycogen synthase kinase GSK3 modulates erythrocyte invasion and blocks gametocyte maturation. J. Biol. Chem. 298, 102360 (2022).
Article CAS PubMed PubMed Central Google Scholar
Galal, K. A. et al. Identification of novel 2,4,5-trisubstituted pyrimidines as potent dual inhibitors of plasmodial Pf GSK3/ Pf PK6 with activity against blood stage parasites in vitro. J. Med. Chem. 65, 13172–13197 (2022).
Article CAS PubMed PubMed Central Google Scholar
Moolman, C., Van Der Sluis, R., Beteck, R. M. & Legoabe, L. J. Exploration of benzofuran-based compounds as potent and selective Plasmodium falciparum glycogen synthase kinase-3 (PfGSK-3) inhibitors. Bioorg. Chem. 112, 104839 (2021).
Article CAS PubMed Google Scholar
Fugel, W. et al. 3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3- b]pyridine-5-carbonitriles are selective inhibitors of plasmodium falciparum glycogen synthase kinase-3. J. Med. Chem. 56, 264–275 (2013).
Article CAS PubMed Google Scholar
Curt-Varesano, A., Braun, L., Ranquet, C., Hakimi, M.-A. & Bougdour, A. The aspartyl protease TgASP5 mediates the export of the Toxoplasma GRA16 and GRA24 effectors into host cells: TgASP5 is essential for GRA16 and GRA24 export. Cell. Microbiol. 18, 151–167 (2016).
Article CAS PubMed Google Scholar
Huynh, M.-H. & Carruthers, V. B. Tagging of endogenous genes in a toxoplasma gondii strain lacking Ku80. Eukaryot. Cell 8, 530–539 (2009).
Article CAS PubMed PubMed Central Google Scholar
Wilke, G. et al. A stem-cell-derived platform enables complete cryptosporidium development in vitro and genetic tractability. Cell Host Microbe 26, 123–134.e8 (2019).
Article CAS PubMed PubMed Central Google Scholar
Waldman, B. S. et al. Identification of a Master Regulator of Differentiation in Toxoplasma. Cell S0092867419313753 https://doi.org/10.1016/j.cell.2019.12.013.(2020).
Svensson, O., Malbet-Monaco, S., Popov, A., Nurizzo, D. & Bowler, M. W. Fully automatic characterization and data collection from crystals of biological macromolecules. Acta Crystallogr D. Biol. Crystallogr 71, 1757–1767 (2015).
Article ADS CAS PubMed PubMed Central Google Scholar
Bowler, M. W. et al. MASSIF-1: a beamline dedicated to the fully automatic characterization and data collection from crystals of biological macromolecules. J. Synchrotron Rad. 22, 1540–1547 (2015).
Article CAS Google Scholar
Svensson, O., Gilski, M., Nurizzo, D. & Bowler, M. W. Multi-position data collection and dynamic beam sizing: recent improvements to the automatic data-collection algorithms on MASSIF-1. Acta Crystallogr D. Struct. Biol. 74, 433–440 (2018).
Article ADS CAS PubMed PubMed Central Google Scholar
Kabsch, W. XDS. Acta Crystallogr D. Biol. Crystallogr 66, 125–132 (2010).
Article ADS CAS PubMed PubMed Central Google Scholar
McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658–674 (2007).
Article ADS CAS PubMed PubMed Central Google Scholar
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126–2132 (2004).
Article ADS PubMed Google Scholar
Terwilliger, T. C. et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D. Biol. Crystallogr 64, 61–69 (2008).
Article ADS CAS PubMed Google Scholar
Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. The PDB_REDO server for macromolecular structure model optimization. IUCrJ 1, 213–220 (2014).
Article CAS PubMed PubMed Central Google Scholar
Vojtek, A. B. & Hollenberg, S. M. Ras-Raf interaction: two-hybrid analysis. Methods Enzymol. 255, 331–342 (1995).
Article CAS PubMed Google Scholar
Beranger, F. Getting more from the two-hybrid system: N-terminal fusions to LexA are efficient and sensitive baits for two-hybrid studies. Nucleic Acids Res. 25, 2035–2036 (1997).
Article CAS PubMed PubMed Central Google Scholar
Bartel, P., Chien, C.-T., Sternglanz, R. & Fields, S. Using the two-hybrid system to detect protein-protein interactions. in Cellular Interactions in Development: A Practical Approach (ed. Hartley, D. A.) 153–179 (Oxford University Press). (1993).
Fromont-Racine, M., Rain, J. C. & Legrain, P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat. Genet 16, 277–282 (1997).
Article CAS PubMed Google Scholar
Formstecher, E. et al. Protein interaction mapping: a Drosophila case study. Genome Res 15, 376–384 (2005).
Article CAS PubMed PubMed Central Google Scholar
Wojcik, J., Boneca, I. G. & Legrain, P. Prediction, assessment and validation of protein interaction maps in bacteria. J. Mol. Biol. 323, 763–770 (2002).
Article CAS PubMed Google Scholar
Rain, J.-C. et al. The protein–protein interaction map of Helicobacter pylori. Nature 409, 211–215 (2001).
Article ADS CAS PubMed Google Scholar
Mair, A., Xu, S.-L., Branon, T. C., Ting, A. Y. & Bergmann, D. C. Proximity labeling of protein complexes and cell-type-specific organellar proteomes in Arabidopsis enabled by TurboID. eLife 8, e47864 (2019).
Article CAS PubMed PubMed Central Google Scholar
Bouyssié, D. et al. Proline: an efficient and user-friendly software suite for large-scale proteomics. Bioinformatics 36, 3148–3155 (2020).
Article PubMed PubMed Central Google Scholar
Couté, Y., Bruley, C. & Burger, T. Beyond target–decoy competition: stable validation of peptide and protein identifications in mass spectrometry-based discovery proteomics. Anal. Chem. 92, 14898–14906 (2020).
Article PubMed Google Scholar
Yu, D., Chojnowski, G., Rosenthal, M. & Kosinski, J. AlphaPulldown—a python package for protein–protein interaction screens using AlphaFold-Multimer. Bioinformatics 39, btac749 (2023).
Article CAS PubMed Google Scholar
Hulsen, T., De Vlieg, J. & Alkema, W. BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 9, 488 (2008).
Article PubMed PubMed Central Google Scholar
Mauri, M., Elli, T., Caviglia, G., Uboldi, G. & Azzi, M. RAWGraphs: A Visualisation Platform to Create Open Outputs. in Proceedings of the 12th Biannual Conference on Italian SIGCHI Chapter 1–5 (Association for Computing Machinery, 2017).
Letunic, I. & Bork, P. Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic tree display and annotation tool. Nucleic Acids Res 52, W78–W82 (2024).
Article PubMed PubMed Central Google Scholar
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Article CAS PubMed Google Scholar
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We are grateful to the developers of the ToxoDB.org Genome Resource. ToxoDB and EuPathDB are part of the National Institutes of Health/National Institutes of Allergy and Infectious Diseases (NIH/NIAID)-funded Bioinformatics Resource Center. This work used the platforms of the Grenoble Instruct-ERIC center (ISBG; UAR 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB), supported by FRISBI (ANR-10-INBS-0005-02) and GRAL, financed within the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). We thank Aline Le Roy for assistance with the OMNISEC data collection. We acknowledge the European Synchrotron Radiation Facility for provision of beam time on ID30-A1/MASSIF-1. This work was supported by MSD Avenir [Project LatentToxoDiag, DS-2022-0017, M-A.H.], the Laboratoire d’Excellence (LabEx) ParaFrap [ANR-11-LABX-0024, M-A.H.], the Agence Nationale pour la Recherche [Project ApiNewDrug, ANR-21-CE35-0010-01, M-A.H.; Project ApiMORCing [ANR-21-CE15-0002-01, M-A.H.]; Project ToxoP53 [ANR-19-CE15-0026, A.B.], Fondation pour la Recherche Médicale [FRM Equipe, EQU202103012571, M-A.H.], and the European Partnership Animal Health & Welfare-SOA19 [Grant Agreement No 101136346, F.L.]. MS-based proteomic experiments were partially supported by Agence Nationale de la Recherche under projects ProFI (Proteomics French Infrastructure, ANR-10-INBS-08, Y.C.) and GRAL, a program from the Chemistry Biology Health (CBH) Graduate School of University Grenoble Alpes [ANR-17-EURE-0003, Y.C.].

Author information

These authors contributed equally: Silvia Diaz-Martin, Christopher Swale.

Authors and Affiliations

Institute for Advanced Biosciences (IAB), Team Host-pathogen interactions and immunity to infection, INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France
Silvia Diaz-Martin, Christopher Swale, Valeria Bellini, Marie-Pierre Brenier-Pinchart, Laurence Braun, Charlotte Corrao, Mohamed-Ali Hakimi & Alexandre Bougdour
INRAE, Université François Rabelais de Tours, Centre Val de Loire, UMR1282 ISP, Laboratoire Apicomplexes et Immunité Mucosale, Nouzilly, France
Irina Dobrescu, Janine Wenker & Fabrice Laurent
University Grenoble Alpes, CEA, INSERM, UA13 BGE, CNRS, CEA, Grenoble, France
Alwéna Tollec & Yohann Couté
Integrated Structural Biology Grenoble (ISBG) CNRS, CEA, Université Grenoble Alpes, EMBL, 71 avenue des Martyrs, Grenoble, France
Caroline Mas
European Molecular Biology Laboratory, Grenoble, 71 Avenue des Martyrs, CS 90181, Grenoble, France
Matthew Bowler

Authors

Silvia Diaz-Martin
View author publications
Search author on:PubMed Google Scholar
Christopher Swale
View author publications
Search author on:PubMed Google Scholar
Valeria Bellini
View author publications
Search author on:PubMed Google Scholar
Irina Dobrescu
View author publications
Search author on:PubMed Google Scholar
Janine Wenker
View author publications
Search author on:PubMed Google Scholar
Marie-Pierre Brenier-Pinchart
View author publications
Search author on:PubMed Google Scholar
Laurence Braun
View author publications
Search author on:PubMed Google Scholar
Alwéna Tollec
View author publications
Search author on:PubMed Google Scholar
Charlotte Corrao
View author publications
Search author on:PubMed Google Scholar
Yohann Couté
View author publications
Search author on:PubMed Google Scholar
Caroline Mas
View author publications
Search author on:PubMed Google Scholar
Fabrice Laurent
View author publications
Search author on:PubMed Google Scholar
Matthew Bowler
View author publications
Search author on:PubMed Google Scholar
Mohamed-Ali Hakimi
View author publications
Search author on:PubMed Google Scholar
Alexandre Bougdour
View author publications
Search author on:PubMed Google Scholar

Contributions

Conceptualization: C.S., M-A.H., F.L., and A.B. Methodology: S.D-M., V.B., C.S., F.L., C.M., Y.C., V.B., M.B. and A.B. Investigation: S.D-M., C.S., V.B., I.D., J.W., M-P.B-P., A.T., L.B., C.C., C.M., M.B., and A.B. Funding acquisition: F.L., M-A.H. and A.B. Supervision: C.S., V.B., M-P.B-P., Y.C., F.L., M.B., M-A.H., and A.B. Writing—original draft: S.D-M., C.S., Y.C., F.L., M-A.H., and A.B. All authors discussed the results and commented on the manuscript.

Corresponding authors

Correspondence to Mohamed-Ali Hakimi or Alexandre Bougdour.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Peer review

Peer review information

Nature Communications thanks Case McNamara, Grzegorz Popowicz and Christian Doerig for their contribution to the peer review of this work. A peer review file is available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information (download PDF )

Description Of Additional Supplementary File (download PDF )

Supplementary Data 1 (download XLSX )

Supplementary Data 2 (download XLSX )

Supplementary Data 3 (download XLSX )

Supplementary Data 4 (download XLSX )

Supplementary Data 5 (download XLSX )

Reporting Summary (download PDF )

Transparent Peer Review file (download PDF )

Source data

Source data (download XLSX )

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Diaz-Martin, S., Swale, C., Bellini, V. et al. Structural and functional characterization of TgGSK3, a druggable kinase in Toxoplasma gondii. Nat Commun 16, 9765 (2025). https://doi.org/10.1038/s41467-025-64701-7

Download citation

Received: 20 January 2025
Accepted: 24 September 2025
Published: 05 November 2025
Version of record: 05 November 2025
DOI: https://doi.org/10.1038/s41467-025-64701-7